Skip to main content

Table 1 Relationship between FST expression and clinicopathologic characteristics in BCs from TCGA. [N = 935]

From: Down-regulated FST expression is involved in the poor prognosis of triple-negative breast cancer

Characteristics No. of patients Number of positive FST (%) p-value
Age 0.066
  ≤ 45 153 144 (94.1)
  > 45 782 698 (89.3)
Ethnicity# 0.521
 Hispanic/Latino 32 28 (87.5)
 Not Hispanic/Latino 744 676 (90.9)
Pathological stage# 0.415
 I/II 689 618 (89.7)
 III/IV 236 216 (91.5)
Tumor size 0.843
 T1/T2 776 699 (90.1)
 T3/T4 149 135 (90.6)
Lymph node# 0.143
 Negative 427 379 (88.8)
 Positive 490 449 (91.6)
Distant metastasis# 0.845
 Negative 771 696 (90.3)
 Positive 18 16 (88.9)
ER status# 0.659
 Negative 264 240 (90.9)
 Positive 667 600 (90.0)
PR status# 0.260
 Negative 161 149 (92.5)
 Positive 772 692 (89.6)
HER2 status# 1.000
 Negative 531 472 (88.9)
 Positive 162 144 (88.9)
Molecular subtype 0.029*
 HR positive BC 808 734 (90.8)
 HER–2 positive BC 36 28 (77.8)
 TNBC 91 80 (87.9)
Histological subtype# 0.003*
 Infiltrating ductal BC 655 590 (90.1)
 Infiltrating lobular BC 192 180 (93.8)
 Mixed BC 24 23 (95.8)
 Medullary BC 3 3 (100.0)
 Metaplastic BC 5 4 (80.0)
 Mucinous BC 16 10 (62.5)
 Others 39 31 (79.5)
Survival status 0.011*
 Alive 851 773 (90.8)
 Dead 84 69 (82.1)
  1. #The composition ratio is less than 100%; *p < 0.05, statistical significance